Ovid Therapeutics Reports Q3 2025 Financial Results

Ovid Therapeutics ( (OVID) ) has released its Q3 earnings. Here is a breakdown of the information Ovid Therapeutics presented to its investors.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain conditions with significant unmet needs, operating primarily in the pharmaceutical industry. In its latest earnings report for the quarter ending September 30, 2025, Ovid Therapeutics highlighted a challenging financial period marked by a significant net loss. The company reported a net loss of $12.2 million for the third quarter and $27.1 million for the first nine months of 2025, reflecting ongoing challenges in its operations and development programs. The company’s financial performance was characterized by a decrease in cash and cash equivalents, which stood at $20.6 million as of September 30, 2025, down from $26.3 million at the end of 2024. Total revenue for the nine months ended September 30, 2025, was $6.5 million, a notable increase from $490,000 in the same period of the previous year, primarily due to license and other revenue. However, operating expenses remained high, with research and development expenses totaling $18.9 million for the first nine months of 2025. Ovid Therapeutics has taken steps to address its financial challenges, including a private placement completed in October 2025, which raised $75.7 million. This funding is expected to support the company’s operations and development programs for more than 12 months. Despite the financial hurdles, the company remains focused on its strategic goals, including the development of novel drug candidates and potential regulatory approvals. Looking ahead, Ovid Therapeutics’ management remains committed to advancing its pipeline of drug candidates and exploring additional funding opportunities to support its long-term objectives. The company acknowledges the risks and uncertainties inherent in the pharmaceutical industry, including regulatory challenges and the need for additional capital, but is optimistic about its future prospects.